Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Quest Diagnostics (DGX) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
July 23, 2024 6:46 AM EDTQuest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.35, $0.02 better than the analyst estimate of $2.33. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Quest Diagnostics sees FY2024 EPS of $8.80-$9.00, versus the consensus of... More
